#GI25 Another trial unfortunately negative ➖for our patients with pancreas cancer.

As mentioned, innovation is needed.

💡✔️The @PanCAN is a great platform to study novel drugs.

While mechanistically, #Pamrevlumab was of value to study, it didn’t improve survival. @OncoAlert
#GI25 #Pamrevlumab